The latest market price list of bimekizumab in 2025

Bimekizumab (Bimekizumab), as a new type of immunotherapy drug, has been approved for the treatment of moderate to severe psoriasis and has also shown potential in the treatment of other immune diseases. The main mechanism of action of bichizumab is to inhibit the excessive response of the immune system, reduce the inflammatory response, and help patients control immune-mediated diseases such as psoriasis by targeting the two cytokines IL-17A and IL-17F.

Bicizumab can significantly reduce the area of skin lesions, relieve symptoms such as erythema, scales, and itching during the treatment of psoriasis, and help patients restore their normal skin appearance. Compared with traditional treatments, cizumab has a longer duration of efficacy. In the early stages of treatment, patients can clearly feel the effects, and these effects usually last for a long time. Compared with some traditional immunosuppressive drugs, bicizumab has fewer side effects. Many patients do not experience serious side effects during treatment, and adverse reactions are usually mild. By effectively controlling psoriasis symptoms, bicizumab can significantly improve patients' quality of life and reduce the psychological and social distress caused by skin lesions.

Regarding the market price, bicizumab is currently on the market in China, but has not yet been included in medical insurance reimbursement. The domestic price is about three to four thousand yuan per box, and the specification is 160mg per tube. Compared with overseas prices, domestic prices are relatively affordable. Overseas, the price of cizizumab is relatively high, with two 160 mg tubes priced at approximately RMB 40,000 to RMB 50,000. The specific price is affected by exchange rate fluctuations.

Currently, there are no generic drugs of bicizumab on the market. Although its original drug is more expensive, it still has obvious advantages over traditional immunosuppressive treatment. Therefore, many patients are willing to accept this new treatment, especially those with moderate to severe psoriasis who have not responded well to other treatments.

Reference materials:https://www.drugs.com/bimekizumab.html